Dapagliflozin for the treatment of type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Dapagliflozin for the treatment of type 2 diabetes.

Dapagliflozin for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q34262543

about

Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Dapagliflozin for the treatment of type 2 diabetes: a review of the literature CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Antidiabetic agents: past, present and future.Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition.Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.

P2860

Q27015789-27FFF5EF-7FD0-47EE-BFD9-1DE4A4C3B243 Q30426407-309E5006-F647-4E9E-B392-A62114BCA82C Q34710819-4C3D1833-A86D-4053-85BD-AA71B86A9935 Q38059889-861078CC-54F5-4C44-B916-4FE8D010D0BD Q38089737-3705E89B-DD50-43EA-91D9-275E6F5F9DDC Q38092275-F6365D17-2D8C-44B2-87BC-6CEE7889A206 Q38364908-DCBD0C4F-C450-4996-92D6-EF405E7C0F57 Q38429845-3F3D4E1D-16F0-4926-B0D5-7069127DFF79 Q38908779-F414CB9C-7D29-42FB-B61E-428FCFC0BD57 Q42554440-AAABA7BD-867A-466C-BB35-4BEF7163FC69 Q47701628-23523371-6735-4B43-A0A5-2682E3C7F9EB Q48015498-72FCE6B2-D0E9-43A4-95A3-F89646C73772

P2860

Dapagliflozin for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q34262543

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Dapagliflozin for the treatment of type 2 diabetes.

@ast

Dapagliflozin for the treatment of type 2 diabetes.

@en

Dapagliflozin for the treatment of type 2 diabetes.

@nl

type

label

Dapagliflozin for the treatment of type 2 diabetes.

@ast

Dapagliflozin for the treatment of type 2 diabetes.

@en

Dapagliflozin for the treatment of type 2 diabetes.

@nl

prefLabel

Dapagliflozin for the treatment of type 2 diabetes.

@ast

Dapagliflozin for the treatment of type 2 diabetes.

@en

Dapagliflozin for the treatment of type 2 diabetes.

@nl

P1433

Q34262543-BD6E942B-BC52-4A2E-B4F6-EC651F9C1C90

P1476

Q34262543-88BFE503-AE19-4FE0-BD4D-DBB6D9F14CDE

P2093

Q34262543-7E6EBE4F-E607-4C0E-8B57-9F28BBA7AF95

Q34262543-A1237D6B-94FA-4815-85B1-6BDAFC9E6615

P2860

Q34262543-16F428A8-F4D2-4D59-B617-865EE637B864

Q34262543-1C309266-ABAD-4EEC-8825-B9F31FB1DFAD

Q34262543-23B938F5-5C3C-44BD-B8DA-D05FBF5BE0AB

Q34262543-303B31C2-7B97-4A0C-8FB5-0102B7B8FE84

Q34262543-439670E4-0831-4AF9-84ED-667A001E18E7

Q34262543-490E1C00-2D0F-4F33-9F2B-3342A6138055

Q34262543-5128EFEC-5F90-491C-896F-4F20C18F9FF1

Q34262543-795269D3-5AC3-4868-9798-4C95D0F8F5DF

Q34262543-830B0B76-EB13-4AC9-90C9-91354635C782

Q34262543-A64454F8-7AAA-4555-8226-0F86DA5D143E

P304

Q34262543-4858904B-AB6A-4F78-AD4A-7432A5130C4D

P31

Q34262543-794606F4-F081-44E4-89EA-37639A282538

P356

Q34262543-D3DBB449-643F-4D6E-999C-9056AF52C84E

P407

Q34262543-C0BBC5A0-4262-4971-9882-01490CD74AD2

P433

Q34262543-1D0633E1-2E67-4C5C-A428-CA3F68C285EC

P478

Q34262543-971062AA-6B9D-4358-97B3-54247DB4D9A6

P577

Q34262543-FF6E4535-999A-459F-8524-4311082D5FBC

P698

Q34262543-1F7D23E0-EF52-43A9-B116-5CDA6426763A

P921

Q34262543-1C129166-0638-4A97-9020-819023C6E388

P356

P1433

Annals of Pharmacotherapy

P1476

Dapagliflozin for the treatment of type 2 diabetes.

@en

P2093

Joel C Marrs

http://www.w3.org/2001/XMLSchema#string

Sarah L Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

The sodium/glucose cotransport family SLC5

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

P304

590-598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1Q538

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22433611

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes